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Abstract:
Background: Maintaining quality of life including physical functioning is 
highly prioritized among older cancer patients. Geriatric assessment is a 
recommended approach to identify patients with increased vulnerability 




functioning in older cancer patients has scarcely been investigated. 
Aim: Focusing on physical functioning and global quality of life, we 
investigated if frailty identified by a geriatric assessment was associated 
with higher risk of quality of life deterioration during cancer treatment 
and follow-up. 
Design: Prospective, observational study. Patients were classified as frail 
or non-frail by a modified geriatric assessment. Quality of life was 
measured using the European Organisation for Research and Treatment 
of Cancer Core Quality of Life Questionnaire at inclusion, 2, 4, 6 and 12 
months. 
Setting: Eight Norwegian outpatient cancer clinics. 
Participants: Patients ≥70 years with solid tumours referred for palliative 
or curative systemic medical cancer treatment. 
Results: Among 288 patients included, 140 (49%) were frail and 148 
(51%) non-frail. Frail patients consistently reported poorer scores on all 
functioning and symptom scales. Independent of age, gender and major 
cancer related factors, frail patients had significantly poorer physical 
functioning and global quality of life during follow-up, and opposed to 
non-frail patients they had both a clinically and statistically significant 
decline in physical functioning from baseline until 12 months. 
Conclusion: Geriatric assessment identifies frail patients with increased 
risk of physical decline, poor functioning and high symptom burden 
during and following cancer treatment.  Frail patients should therefore 
receive early supportive or palliative care. 
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Background: Maintaining quality of life including physical functioning is highly prioritized 
among older cancer patients. Geriatric assessment is a recommended approach to identify 
patients with increased vulnerability to stressors (frailty). How frailty affects quality of life 
and physical functioning in older cancer patients has scarcely been investigated. 
Aim: Focusing on physical functioning and global quality of life, we investigated if frailty 
identified by a geriatric assessment was associated with higher risk of quality of life 
deterioration during cancer treatment and follow-up.
Design: Prospective, observational study. Patients were classified as frail or non-frail by a 
modified geriatric assessment. Quality of life was measured using the European Organisation 
for Research and Treatment of Cancer Core Quality of Life Questionnaire at inclusion, 2, 4, 6 
and 12 months. 
Setting: Eight Norwegian outpatient cancer clinics.
Participants: Patients ≥70 years with solid tumours referred for palliative or curative systemic 
medical cancer treatment. 
Results: Among 288 patients included, 140 (49%) were frail and 148 (51%) non-frail. Frail 
patients consistently reported poorer scores on all functioning and symptom scales. 
Independent of age, gender and major cancer related factors, frail patients had significantly 
poorer physical functioning and global quality of life during follow-up, and opposed to non-
frail patients they had both a clinically and statistically significant decline in physical 
functioning from baseline until 12 months. 
Conclusion: Geriatric assessment identifies frail patients with increased risk of physical 
decline, poor functioning and high symptom burden during and following cancer treatment.  
Frail patients should therefore receive early supportive or palliative care.
Keywords: geriatric assessment, frailty, quality of life, cancer, observational study, EORTC 
QLQ-C30.
What is already known on the topic?
Frailty identified by geriatric assessment is associated with increased risk of death and 
treatment complications in older cancer patients.
Although geriatric assessment is recommended for older cancer patients it is rarely 
implemented into clinical practice. 
Studies investigating the impact of frailty on highly relevant outcomes like physical 
functioning and quality of life are scarce.
What this paper adds? (outcome)

































































Frailty identified by geriatric assessment independently predicts a clinically significant 
decline in physical functioning.
Frailty is associated with worse global quality of life, poorer functioning and a higher 
symptom burden throughout the cancer trajectory
Implication for practice, theory, or policy
Including routine geriatric assessment for older cancer patients undergoing systemic medical 
cancer treatment will aid oncologists in identifying frail patients who need early supportive 
and palliative care. 


































































Prolonging survival is usually considered the main goal of cancer care. However, maintaining 
or improving quality of life can be equally important. This applies especially to older patients, 
who have poorer survival in comparison with their younger counterparts and may be less 
willing to exchange current quality of life for smaller survival benefits1, 2. The quality of life 
concept embraces multiple dimensions: emotional, social, existential as well as physical, the 
latter including aspects such as patient reported somatic symptoms and physical functioning. 
Physical functioning is strongly associated with independent living, which is highly 
prioritized among older patients 3, 4, and is also a key driver for how they perceive their 
overall quality of life 5, 6. Thus, making appropriate treatment decisions for older cancer 
patients requires knowledge on how quality of life may be affected and ability to identify 
patients at risk of deterioration. Particular attention to physical functioning seems essential. 
Frailty is defined as increased vulnerability to adverse changes in health status 7, and is 
associated with increased mortality, postoperative complications and intolerance to cancer 
treatment 8, 9. Frail patients have been found to have poorer quality of life than non-frail 
patients10-12, but longitudinal studies investigating the impact of frailty on quality of life 
during and after cancer treatment are scarce. Results from those available are not consistent, 
having shown both similar changes in quality of life trajectories of frail and non-frail patients 
10, 11 as well as accelerated decline of some dimensions among frail patients 13.
A challenge to all frailty research is the lack of universally accepted operational criteria. Over 
70 different methods for measuring frailty have been developed, most of which are linked to 
the two dominating pathophysiological theories of frailty; the physical frailty phenotype and 
the cumulative deficit model14, 15. In the oncology literature, geriatric assessment  is the 

































































recommended approach to identifying frailty 14 and to guide treatment decisions for older 
patients 16. This approach includes a systematic assessment of areas such as functional status, 
mobility, cognitive function, comorbidity and geriatric syndromes 8, 16. Still, geriatric 
assessment remains to be widely implemented into oncology practice, perhaps hampered by 
its comprehensiveness. Simpler frailty screening tools are more time-efficient and might be 
easier to implement into clinical practice, but their lower sensitivity and specificity is a 
challenge 17. Thus, geriatric assessment is considered the gold standard,14 although screening 
tools may be used to select patients for a complete geriatric assessment18. There is, however, 
no general agreement on how frailty should be defined based on a geriatric assessment. 
Varying domains and thresholds have been applied in different studies8, but the criteria as 
proposed by Balducci et al 19 have commonly been used 20, 21.
We have formerly demonstrated that frailty identified by a modified geriatric assessment and 
a modification of the Balducci criteria 22, 23, was independently predictive of survival in 
cancer patients > 70 years of age 24. In the present study, targeting the same population, we 
aimed at investigating if frailty was associated with higher risk of quality of life deterioration 
during treatment and follow-up. Our main hypothesis was that patients classified as frail upon 
start of treatment would experience a steeper decline in both physical functioning and global 
quality of life than non-frail patients.
Materials and methods
Patients
Patients were consecutively recruited from January 2013 until April 2015 at eight Norwegian 
outpatient oncology clinics (two university hospitals and six local hospitals). Eligible patients 
were ≥70 years and referred for systemic medical cancer treatment (chemotherapy, hormonal 

































































or targeted therapy) with a histologically confirmed solid tumour (newly diagnosed or first 
relapse after previous curative treatment). Patients provided written, informed consent. 
Assessments
Oncologists reported cancer type (ICD-10), stage of disease, planned treatment and ECOG 
performance status. Data on administered treatment were retrieved from the patients’ medical 
records. 
Physical functioning and global quality of life was assessed by the European Organisation for 
Research and Treatment of Cancer Quality of Life Core Questionnaire (QLQ-C30) 25 at 
inclusion, and after 2, 4, 6, and 12 months. QLQ-C30 consists of 30 questions comprising five 
functioning scales, nine symptom scales/items and a global quality of life scale. The 
functioning scales include physical, role, social, cognitive and emotional functioning. 
Symptoms include fatigue, pain, nausea/vomiting, sleep disturbances (insomnia), appetite 
loss, diarrhoea, dyspnoea and constipation, and financial impact. The raw scores are 
transformed into scales from 0 to 100 points 26. Higher scores on the functioning and global 
quality of life scales represent better functioning, whereas higher scores on symptom 
scales/items indicate a higher symptom burden.
Frailty was identified by a geriatric assessment which we have referred to as modified since it 
was not performed by an interdisciplinary team, but by trained oncology nurses and patients’ 
self-report, 24 using well-known and validated instruments for each included domain 27-31 
(Table 1). Our frailty definition was predefined and following the Balducci criteria, patients 
were categorized as frail if they fulfilled at least one of the following; dependencies in 
activities of daily living, significant comorbidity or one or more geriatric syndromes 
(cognitive function, depression, malnutrition, falls). Similar to Kristjansson et al 22, we 

































































included polypharmacy as a criterion, and added impairment according to Timed Up and Go 
27, a sensitive and specific measure of frailty 32. Cut-off values for each domain were chosen 
in line with former reports and practice (Table 1) 23, 33-40. A detailed explanation is found in a 
previous paper 24. To screen for deficits in activities of daily living a question from the QLQ-
C30 physical functioning scale (“Do you need help with eating, dressing, washing yourself or 
using the toilet?”) were used.
Statistical analyses 
Medical and sociodemographic factors were compared between frail and non-frail patients by 
independent samples t-tests or χ2-test.
Our predefined main endpoints were changes in physical functioning during the two first 
months of follow-up (primary), and changes in physical functioning and global quality of life 
during 12 months (secondary). Changes du ing 12 months for the remaining QLQ-C30 scales 
and items were assessed by exploratory analyses using the same approach as for the main 
endpoints. 
Differences between frail and non-frail patients in changes over time were assessed by linear 
mixed models. All models included random intercepts for cancer clinics and for patients 
nested within cancer clinics to account for intra-patient correlations due to repeated 
measurements and possible within-clinic cluster effect. The models also included fixed effects 
for frailty group, time (as second-order polynomial to account for non-linear trends in models 
assessing data on 12 months follow-up) and the interaction term between frailty group and 
time (frail*time). A significant interaction term would imply that there were differences in 
change between frail and non-frail patients. Models adjusting for age, sex, cancer type, 
performance status, stage and treatment were also estimated. Treatment was classified as; 1) 

































































Curative treatment, i.e. patients referred for neoadjuvant chemotherapy treatment, adjuvant 
chemotherapy and/or endocrine treatment after curative surgery or curative radiotherapy, 2) 
palliative chemotherapy, 3) other palliative systemic cancer treatment, 4) non-systemic 
palliative treatment the first two months after inclusion (i.e. radiotherapy, surgery or palliative 
care). Performance status was classified as 0-1 or 2-4, and stage as local, locally advanced or 
metastatic. The results were tabulated as regression coefficients with standard errors (SE) and 
p-values for the primary and secondary analyses of physical functioning and global quality of 
life. The results from unadjusted models were also presented graphically as estimated mean 
values with 95% confidence intervals (CI) for all QLQ-C30 scales/items. Within- and 
between-group differences with the corresponding 95% CI and p-values were calculated from 
the models. Significance level was set at 5%. A difference of ≥10 points on the functional and 
symptom scales/items was considered a clinically significant change 41. 
Missing values in QLQ-C30 multi-item scales were imputed according to the official manual 
if at least half of the scale had been answered 26. 
The study was approved by the Regional Committee for Medical and Health Research Ethics 




From January 2013 to April 2015 a total of 307 patients were included. One patient withdrew 
consent and 18 had missing baseline questionnaires and therefore incomplete geriatric 
assessments. Thus, 288 (94%) patients were eligible for the present frailty study. A total of 
140 patients (49%) fulfilled one or more of the predefined criteria and were categorized as 

































































frail. The most frequent deficits were comorbidity (n = 82, 28%), malnutrition (n = 43, 15%), 
polypharmacy (n = 37, 13%) and depressive symptoms (n = 35, 12%). Forty patients (14%) 
had deficits in physical functional aspects: activities of daily living (12 patients), Timed Up 
and Go (18 patients) and number of falls (10 patients). Nine patients (3%) had cognitive 
impairment. Of the 140 patients categorized as frail, 67 (48%) patients had two or more 
registered deficits. Only one patient was classified frail based on the activities of daily living 
criterion alone, which was screened for by using question 5 from the physical functioning 
scale of QLQ-C30. 
The patients’ baseline characteristics are shown in Table 2. Mean age was 76.9 (5.1) years, 
56% were male, the most common cancer types were colorectal (29%), lung (21%) and 
prostate cancer (19%). The majority of patients had distant metastases (56%), and overall, 
68% received palliative treatment. A higher percentage of frail compared to non-frail patients 
had lung cancer, distant metastases, performance status 2-4 and received palliative 
chemotherapy.
At 2, 4, 6 and 12 months of follow-up, 13 (5%), 27 (9%), 52 (18%) and 93 (32%) patients of 
the overall cohort had died. Median overall survival was shorter among frail than non-frail 
patients (15 vs 29 months) 24. The first 12 months, 83 (59%) of frail and 112 (76%) of non-
frail patients were alive, resulting in relative risk of death of 1.7 (95% CI 1.2; 2.4) for frail 
compared to non-frail patients. The proportion of completed questionnaires ranged between 
89% and 95% for those alive at the various assessment points (Figure 1). The mean 
proportion of missing items ranged from 0.51% to 0.96%.


































































At baseline, frail patients reported poorer functioning and more symptoms than non-frail 
patients on all scales/items (Table 2). 
Both frail and non-frail patients reported a statistically, but not clinically significant decline in 
physical functioning from baseline to two months. The decline was not significantly different 
between frail and non-frail patients (unadjusted model: p = 0.181, adjusted model: p = 0.218). 
According to the unadjusted linear mixed model, there were, however, statistically significant 
differences in physical functioning scores between the two groups in disfavour of frail 
patients, mean 18.2 (CI 13.3; 23.1) points at baseline and 15.0 (CI 9.9; 20.0) points at two 
months (p<0.001) (Figure 2, Table 3a). The differences remained statistically significant 
when adjusting for age, gender, cancer type, stage, performance status and treatment (12.2 (CI 
7.5; 16.9) points at baseline, 9.2 (CI 4.4; 14.1) at two months) (p<0.001) (Figure 2, Table 3a). 
For our secondary endpoint, physical functioning during 12 months of follow-up, a 
statistically significant decline was found for non-frail patients from baseline to 6 months, and 
for frail patients from baseline to both 6 and 12 months. Only frail patients had a clinically 
significant (≥10 points) decline. In unadjusted models the decline in physical functioning for 
frail and non-frail patients was not significantly different (p=0.089) (Table 3b, Figure 2). 
However, when adjusting for age, gender, cancer type, stage, performance status and 
treatment, the decline was found to be significantly steeper for frail patients (p=0.022) (Table 
3b). Thus, the observed difference in scores in disfavour of frail patients during the two first 
months increased throughout the follow-up period and remained statistically and clinically 
significant, both according to unadjusted (Figure 2, Table 3b) and adjusted models (Table 3b) 
(p < 0.001). 

































































For global quality of life during 12 months of follow-up, there was no significant difference 
between frail and non-frail patients in the course of changes (p = 0.369 in unadjusted models; 
p = 0.273 in adjusted models) (Table 3c). Both models demonstrated that frail patients had 
statistically and clinically significantly worse scores compared to non-frail patients at all 
assessment points (p<0.001) (Figure 2, Table 3c).
Unadjusted trajectories for frail and non-frail patients for the remaining functioning and 
symptom scales are shown in Figure 2 and 3. Differences that were both statistically and 
clinically significant according to unadjusted and adjusted analyses are indicated. In the 
adjusted model, frail patients had a clinically and statistically significant decline in role 
functioning from baseline to six months (p<0.001). None of the other scales showed any 
clinically significant changes from baseline in the adjusted models, neither in frail nor non-
frail groups. Except for diarrhoea (adjusted model, p = 0.023), with a statistically but not 
clinically significant increase in symptoms from baseline to 6 months for frail patients, the 
course of the trajectories was not significantly different between the groups. However, 
adjusted models showed that frail patients had statistically and clinically significantly more 
constipation (p < 0.01), and worse role - (p<0.001), social (p<0.01), and emotional 
functioning (p<0.01) at all assessments. Accordingly, significant differences between the 
frailty groups were found at some but not all assessment points for dyspnoea, insomnia, 
appetite loss and fatigue (Figure 3). 
Discussion 
In this longitudinal study, older cancer patients were assessed by a modified geriatric 
assessment, and we identified a group of frail patients who in comparison to non-frail patients 

































































had substantially poorer functioning and more symptoms. Independent of age, gender and 
major cancer related prognostic factors, they reported significantly worse global quality of 
life, physical-, role-, social, - and emotional functioning, and more constipation during 
treatment and follow-up. They also reported a long-term decline in physical functioning that 
was clinically significant, and significantly steeper than for non-frail patients. 
To the best of our knowledge, the present study is the first to report a longitudinal comparison 
of self-reported physical functioning between frail and non-frail older patients mainly 
receiving systemic cancer therapy, and the first to suggest a more profound deterioration in 
this quality of life dimension among frail patients after adjusting for other relevant 
confounders. Our finding is supported by two former studies reporting frailty indicators to be 
predictive of observer rated physical decline in older cancer patients receiving chemotherapy 
or neoadjuvant/adjuvant treatment 42, 43. No such impact of frailty was found in studies of 
patients receiving surgery and radiochemotherapy, respectively 10, 11. In the latter, however, 
specific assessments of physical functioning were reported only at four weeks after start of 
therapy, and as indicated by our results, a significant decline may take longer to develop. It is 
also likely that a protracted course of chemotherapy, which as the treatment received by 
most of our patients, may have a larger impact on frail patients’ physical functioning than 
surgery. 
The results of the few previous studies that have investigated how frail older cancer patients 
perceive their quality of life are largely consistent with our remaining findings. Frail patients 
seem to be at a considerable disadvantage throughout the disease trajectory, reporting a 
substantial symptom burden and poor functioning compared to non-frail patients 10, 11, 44. In 
line with the findings for most quality of life aspects in our cohort, others have also found that 

































































although quality of life is poorer, changes mainly follow a similar course in frail and non-frail 
cancer patients. Increased risks of long-term deterioration has, however, been suggested 13, 44. 
How an observed similarity of changes in quality of life trajectories of frail and non-frail 
patients should be interpreted is not obvious. One might argue that this indicates that frail 
patients tolerate cancer therapy equally to non-frail patients. However, as frail patients are 
worse off from the start, changes of the same magnitude may affect these patients more 
profoundly than those who are non-frail.
Our study has several strengths, i.e. a fairly large patient cohort, 12 months follow-up, use of 
a well-validated quality of life-questionnaire, high completion rate, and statistics controlling 
for major factors that may affect quality of life. Still, the results should be interpreted with 
some caution. Firstly, the population was heterogeneous, details of the chemotherapy 
regimens were not accounted for, and we cannot rule out that frail patients received modified 
or less aggressive regimens than those who were non-frail. This is, however, unlikely as the 
physicians were blinded for the results of the modified geriatric assessment. Also, as formerly 
reported, there was only a fair agreement between the frailty classification based on this 
assessment and physician-rated frailty24. Secondly, we were not able to accurately register the 
number of potentially eligible patients who were not included at the various participating 
clinics. According to the project nurses, however, non-inclusion mainly occurred by random 
due to lack of time to identify and include patients among their routine clinical tasks. Still, 
there is some risk that the frailest patients with the poorest overall health more often declined 
participation or were less frequently invited to participate due to concerns of the additional 
burden the study tests represented. Thirdly, due to a higher death rate among frail patients, 
attrition bias may have resulted in underestimation of differences between frail and non-frail 
patients 45. Fourthly,  physical function, as assessed by Timed Up and Go, number of falls and 

































































one item from the physical functioning scale of the EORTC QLQ-C30, is a key component of 
a geriatric assessment and frailty definition and can probably explain some of the baseline 
difference we found in functioning between frail and non-frail patients. However, it is not 
inherent in our frailty definition that frail patients experience a steeper decline in physical 
functioning compared to non-frail. Moreover, only a minority of the patients fulfilled these 
criteria, and the main point to be noted is the overall burden of problems among these frail 
patients. An additional point of consideration is that we used one question from the QLQ-C30 
physical functioning scale, which was also our main endpoint, to identify frailty. Only one 
patient was classified as frail based on this criterion alone, hence we believe that this did not 
affect our results. Finally, as there is no consensus on how frailty should be identified, it may 
be discussed if our frailty definition captures the true concept. One may argue that it was too 
broad as only one criterion was needed to be classified as frail. A stricter definition might 
have resulted in larger discrepancies between frail and non-frail patients. However, our 
approach was adapted from the Balducci criteria, and a similar definition was found superior 
to the physical frailty phenotype in identifying postoperative complications in cancer 
patients46. There is a need for standardisations of cut-off-values for frailty8, nevertheless the 
consistency of findings across studies indicates that geriatric assessment can identify patients 
who need particular attention.
Our study shows that frailty as identified by a modified geriatric assessment has a severe 
impact on the patients' quality of life throughout the disease trajectory, independent of cancer 
related factors. Thus, by introducing geriatric assessment into clinical work, a more correct 
individualisation of treatment can be achieved 47. Furthermore, targeted interventions to 
improve quality of life and maintain functioning may be initiated. Early introduction of 
palliative care has been shown to improve quality of life, reduce aggressiveness of treatment 

































































and improve survival 48. Similar studies in frail old cancer patients are needed to examine 
whether improvement of quality of life can be obtained. Ideally these studies should include 
interventions on geriatric deficits and measure their effect on quality of life. Particular 
attention should be paid on avoiding physical decline, which may considerably increase the 
risk of dependency, a predominant fear among older patients 4, 49. As indicated by the findings 
in our study, frail patients report significantly poorer physical functioning than those who are 
non-frail, meaning that any decline is likely to have more serious consequences.  
In conclusion, introducing geriatric assessment into routine clinical practice may help 
oncologists identify patients with significantly worse quality of life, and enable better 
individualisation of treatment. This may also facilitate early and correctly targeted 
interventions. Future research is, however, needed to explore whether intervening on frailty 
domains can improve functional status, global quality of life, symptom burden or tolerance to 
cancer therapy.
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Table 1. The modified Geriatric assessmenta
Area Assessment method Scores Performer
Cut off value above which 
patients were defined as frail




If reported yes a little/quite a 
bit/very much on the question 
“Do you need help with 
eating, dressing, washing 










>7 regular medications 














Nutritional status PG-SGAg Nurse/ Patient
Considered severely 
malnourished by nurse or self-
reported weight loss ≥10% the 
last 6 months.
Falls   Nurse Patient reports ≥2 falls the last 6 months
Physical function TUGh  Nurse >14 seconds
aPatients were classified as frail if having ≥ 1 of the criteria listed in the table, bThe European 
Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire, cThe 
Physical Health Section of the Older Americans’ Resources and Services Questionnaire, 
dAnatomical Therapeutic Chemical Classification System, eNorwegian Revised Mini Mental State 
Examination, fGeriatric depression scale, gPatient-generated Subjective Global Assessment, hTimed 
up and Go test.
































































Table 2. Baseline patient characteristics according to frailty status 
  All Frail Non-frail
  N (288) % N (140) % N(148) % P-value
Age, mean (SD) 76.9(5.1)  77.5(5.2)  76.2(5.0)  0.032*
Gender      
 Female 126 44 64 46 62 42 0.513**
Cancer type      
 Colorectal 83 29 39 28 44 30
 Lung 59 21 35 25 24 16 0.045**
 Prostate 56 19 22 16 34 23
 Other gastrointestinal 34 12 19 14 15 10
 Breast 30 10 9 6 21 14
 Other 26 9 16 11 10 7
Stage      
 Localized 73 25 30 21 43 29 0.091**
 Locally advanced 55 19 23 16 32 22
 Distant metastasis 160 56 87 62 73 49
ECOG Performance status      
 0-1 244 85 106 76 138 93
 2-4 43 15 33 24 10 7 <0.001**
 Missing 1  1    
Treatment      
 Curative*** 91 32 31 22 60 41
 Palliative chemotherapy 126 44 75 54 51 35 0.002**
 Other palliative systemic cancer treatment 51 18 22 16 29 20
 Non-systemic palliative treatment**** 20 7 12 9 8 5
mean SD mean SD mean SD
Functioning scales and global health status
Physical functioning 72.9 21.4 63.5 21.3 81.7 17.4
Global quality of life 64.1 23.1 54.5 22.1 73.4 20.1
Role functioning 65.5 32.1 52.0 31.7 78.4 26.8
Emotional functioning 83.9 18.1 77.7 21.1 89.8 12.2
Cognitive functioning 87.6 16.0 83.6 18.1 91.4 12.7
Social functioning 76.0 25.9 68.3 28.5 83.2 20.9
Symptom scales/items
Fatigue 38.8 24.2 48.7 25.6 29.4 18.5
Nausea and vomiting 6.8 14.8 10.6 18.7 3.3 8.6
Pain 24.8 29.4 32.9 31.7 17.1 24.9
Dyspnea 25.7 31.4 33.3 34.1 18.5 26.8
Insomnia 26.2 28.5 32.1 30.9 20.5 24.8
Appetite loss 21.4 31.4 30.7 36.0 12.6 23.2
Constipation 24.0 29.3 30.5 32.4 17.9 24.8
































































Diarrhoea 15.2 22.4 17.1 24.2 13.2 20.5
*Independent samples t-test **Pearson chi-square ***referred for neoadjuvant treatment, adjuvant 
treatment after curative surgery or curative radiotherapy ****i.e. radiotherapy, palliative surgery or 
palliative care


































































* missing baseline questionnaire (n=18)
* withdrew consent (n=1)
Available for analyses and grouped
according to frailty status (n=288)
Baseline (n=288)
Frail (n=140) Non-frail (n=148)
2 months (n=275 )
Completed QLQ-C30 (n=124) Completed QLQ-C30 (n=133)
Died (n=10) Died (n= 3)
Non-responders (n=6) Non-responders (n=12)
4 months (n=261)
Completed QLQ-C30 (n=118) Completed QLQ-C30 (n=129)
Died (n=6) Died (n=8)
Non-responders (n=6) Non-responders (n=8)
6 months (n=236)
Completed QLQ-C30 (n=102) Completed QLQ-C30 (n=120)
Died (n=16) Died (n=9)
Non-responders (n=6) Non-responders (n=8)
12 months (n=195)
Completed QLQ-C30 (n=74) Completed QLQ-C30 (n=104)
Died (n=25) Died (n=16)
Non-responders (n=9) Non-responders (n=8)
QLQ-C30 = European Organisation for Research and Treatment of Cancer Core Quality of Life
Questionnaire

































































Figure 2.  Global quality of life and function scores for frail and non-frail patients, at baseline and at two, 
four, six and twelve months of follow-up, according to unadjusted mixed linear models. # indicates clinically 
and statistically significant differences in unadjusted models*indicates clinically and statistically significant 
differences in adjusted models For these QLQ-C30 functioning scales, higher scores indicate better 
functioning 
221x173mm (300 x 300 DPI) 
































































Table 3. Linear mixed models of the trajectories of physical functioning in frail versus non-
frail patients during two months of follow up, and of physical functioning and global quality 
of life during the first 12 months of follow-up
Variable Unadjusted model Adjusted model**
 Coefficient SE P-value Coefficient SE P-value
a) Physical functioning* the first two months.
Intercept 81.86 1.73 <0.001 117.90 18.11 <0.001
Frailty (ref.non-frail) † -18.20 2.48 <0.001 -12.21 2.40 <0.001
Time 2 months (ref. baseline) -7.02 1.69 <0.001 -7.36 1.67 <0.001
Frail*Time†† 3.25 2.43 0.181 2.98 2.41 0.218
b)Physical functioning* the first 12 months
Intercept 80.41 1.61 <0.001 124.74 18.52 <0.001
Frailty (ref.non-frail) † -16.80 2.23 <0.001 -10.44 2.31 <0.001
Time -2.03 0.35 <0.001 -2.13 0.35 <0.001
Time2 0.13 0.03 <0.001 0.14 0.03 <0.001
Frail*Time†† -0.40 0.23 0.089 -0.49 0.21 0.022
c) Global quality of life* the first 12 months
Intercept 71.62 1.65 <0.001 87.78 18.62 <0.001
Frailty (ref.non-frail) † -15.27 2.24 <0.001 -12.59 2.37 <0.001
Time -0.83 0.41 0.046 -0.91 0.41 0.029
Time2 0.07 0.03 0.034 0.07 0.03 0.025
Frail*Time†† -0.23 0.25 0.369 -0.28 0.25 0.273
* Physical functioning and global quality of life from the European Organisation for Research 
and Treatment of Cancer Quality of Life Core Questionnaire **Adjusted for age, gender, cancer 
type, stage, performance status and treatment 
† (Frailty (ref non-frail) refers to estimates of the difference in score between frail and non-frail 
patients
†† Frail*Time refers to the interaction term between the frail group and time. A significant 
interaction term implies significant differences in changes over time between frail and non-frail 
patients

































































Figure 3. Symtom scores for frail and non-frail patients, at baseline and at two, four, six and twelve months 
of follow-up, according to unadjusted mixed linear models# indicates clinically and statistically significant 
differences in unadjusted models*indicates clinically and statistically significant differences in adjusted 
models For these QLQ-C30 symptom scales/items, higher scores indicate more symptoms 
221x193mm (300 x 300 DPI) 

































































STROBE Statement—checklist of items that should be included in reports of observational studies
Item 
No Recommendation
(a) Indicate the study’s design with a commonly used term in the title or the abstract
Reported in the design section of the abstract.
Title and abstract 1
(b) Provide in the abstract an informative and balanced summary of what was done 
and what was found 
A balanced summary are written in abstract
Introduction
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported
The background/rationale has been given in the first three paragraphs in the 
introduction
Objectives 3 State specific objectives, including any prespecified hypotheses
Our objective and hypothesis are included in the fourth paragraph of the introduction.
Methods
Study design 4 Present key elements of study design early in the paper
Included in the design section in abstract and in materials and methods.
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, 
exposure, follow-up, and data collection
Described in Patients and Assessments in materials and methods
(a) Cohort study—Give the eligibility criteria, and the sources and methods of 
selection of participants. Describe methods of follow-up
Eligibility criteria are given in the “Patient section” of materials and methods, the 
assessment performed and who performed the assessment are registered in the section 
“Assessment” in materials and methods. In this section we also refer to our previously 
published paper that give further detailed information about our assessments and 
follow-up.
Case-control study—Give the eligibility criteria, and the sources and methods of case 
ascertainment and control selection. Give the rationale for the choice of cases and 
controls
Cross-sectional study—Give the eligibility criteria, and the sources and methods of 
selection of participants
Participants 6
(b) Cohort study—For matched studies, give matching criteria and number of exposed 
and unexposed 
Not relevant for this study
Case-control study—For matched studies, give matching criteria and the number of 
controls per case
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable
Defined in the section “Statistical analyses” of materials and methods
Data sources/ 
measurement
8*  For each variable of interest, give sources of data and details of methods of 
assessment (measurement). Describe comparability of assessment methods if there is 
more than one group

































































In materials and methods in the section “Assessment” details of methods of 
assessment are described. We also refer to a previously published paper that in more 
detail describe our frailty assessment. 
Bias 9 Describe any efforts to address potential sources of bias
Attrition bias have been addressed in the discussion section in the fourth paragraph
Study size 10 Explain how the study size was arrived at
This study was planned with a heterogeneous patient sample and with unknown 
prevalence, distribution, and effect size of variables planned to include in analyses. 
An exact sample size estimate could therefore not be presented in the protocol, and 
only estimates were performed. This has not been included to be able to keep the 
allowed word count of the manuscript.  
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, 
describe which groupings were chosen and why’
This has been explained in “Statistical analyses” in methods section
(a) Describe all statistical methods, including those used to control for confounding
Statistical methods explained in Statistical analyses in methods section
(b) Describe any methods used to examine subgroups and interactions
This is described in Statistical analyses in methods section
(c) Explain how missing data were addressed
This is explained in statistical analyses in methods section. 
(d) Cohort study—If applicable, explain how loss to follow-up was addressed
Missing items were imputed statistically, a description of how many loss to follow-up 
we had at each time were presented in results and attrition bias discussed in the 
discussion section. 
Case-control study—If applicable, explain how matching of cases and controls was 
addressed
Cross-sectional study—If applicable, describe analytical methods taking account of 
sampling strategy
Statistical methods 12
(e) Describe any sensitivity analyses 
- 
Continued on next page


































































(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, 
examined for eligibility, confirmed eligible, included in the study, completing follow-up, and 
analysed
Paragraph one of the Result section describes how many patients were included, and how 
many of these patients were available for analyses. Figure 1 summarize how many that 
completed follow-up questionnaires at each follow-up time.
(b) Give reasons for non-participation at each stage
Number of patients alive at each follow-up point are presented in figure 1, as well as how 
many patients that responded on the follow-up questionnaire. At inclusion we have missing 
information about eligible patients that were not included and this has been discussed as a 
limitation in the discussion section of this manuscript. 
Participants 13*
(c) Consider use of a flow diagram
Figure 1 in the revised manuscript gives an overview of patient enrolment and follow-up.
(a) Give characteristics of study participants (eg demographic, clinical, social) and information 
on exposures and potential confounders
Table 2 and result section “Patients”
(b) Indicate number of participants with missing data for each variable of interest
Patients with missing quality of life questionnaires are reported in figure 1. In our previously 
publication referred to in this manuscript detailed information about missing in frailty 




(c) Cohort study—Summarise follow-up time (eg, average and total amount)
In paragraph 2 of «Patients» in the result section follow-up time are presented.
Cohort study—Report numbers of outcome events or summary measures over time
Figure 1
Case-control study—Report numbers in each exposure category, or summary measures of 
exposure
Outcome data 15*
Cross-sectional study—Report numbers of outcome events or summary measures
(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their 
precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and 
why they were included
Given in Table 4, figure 2 and 3 as well as in text in “Qol analyses” in result section.
(b) Report category boundaries when continuous variables were categorized 
We used continuous variables as appropriate.
Main results 16
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful 
time period
Not relevant
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity 
analyses
Exploratory analyses are presented in “Qol-analyses” in result section.
Discussion
Key results 18 Summarise key results with reference to study objectives
The first paragraph of the Discussion section summarizes key results.

































































Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. 
Discuss both direction and magnitude of any potential bias
Discussed in fourth paragraph of result section.
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity 
of analyses, results from similar studies, and other relevant evidence
Included in the interpretation of the results in the discussion section
Generalisability 21 Discuss the generalisability (external validity) of the study results
Briefly discussed in the discussion as well as in previous publication.
Other information
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, 
for the original study on which the present article is based
Given in “Funding” at the end of the manuscript.
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed 
groups in cohort and cross-sectional studies.
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and 
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely 
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available 
at www.strobe-statement.org.

































































PALLIATIVE MEDICINE AUTHOR SUBMISSION CHECKLIST  
Please complete this checklist for all papers submitted. Please indicate, very briefly, how this has been addressed. This checklist is a 
mandatory upload on submission. 
Item Explanation How this has been addressed 
(briefly, a sentence will suffice)
Article title WHY: Because we want readers to find your work.
Have you followed our guidelines on writing a good title that will be found by search engines? (E.g. with 
methods in the title, use of common words for the issue addressed, no country names, and possibly 
indicating findings). If your study has an acronym is it included in the title?
We have use common words for 
the issue addressed (geriatric 
assessment, physical decline, old, 
cancer) and indicate findings 
from the study.
Abstract WHY: Because structured abstracts have more detail for readers and search engines.
Have you followed our guidelines on writing your structured abstract? Please remember we have 
separate abstract structures for original research, reviews and case reports. There should be no 
abbreviations in the abstract, EXCEPT a study acronym which should be included if you have one. If a trial 
(or other design formally registered with a database) have you included your registration details?
We have followed the guidelines 
and not used abbreviations. 
Key statements WHY: Because readers want to understand your paper quickly.
Have you included our key statements within the body of your paper (after abstract and before the main 
text is a good place!) and followed our guidelines for how these are to be written?   There are three main 
headings required, and each may have 1-3 separate bullet points. Please use clear, succinct, single 
sentence separate bullet points rather than complex or multiple sentences. 
Key statements are included with 
three main headings.
Keywords WHY: Because MeSH headings mean it is properly indexed.
Have you given keywords for your study? We ask that these are current MeSH headings unless there is 
no suitable heading for use (please give explanation in cover letter).  https://meshb.nlm.nih.gov/search 
Five keywords are included, four 
are MeSH headings. One word 
“EORTC QLQ-C30” is not a MeSH 
heading. This keyword is included 
as it is the abbreviation of the 
questionnaire used in our study.  
International 
relevance
WHY: We have readers from around the world who are interested in your work. 
Have you contextualised your work for an international audience and explained how your work 
contributes to an international knowledge base?  Avoid drawing from policy from one context only, think 
how your work could be relevant more widely. Do define terms clearly e.g. hospice has a different 
meaning in many countries. 
All tests and questionnaires that 
are used are internationally 
known, and the article written to 
contribute to international 
knowledge base.



































































WHY: Because clear and robust reporting helps people interpret your work accurately
Have you submitted a completed checklist for a relevant publishing guideline as a supplementary file? 
http://www.equator-network.org/ These include CONSORT, PRISMA, COREQ checklists, but others may 
be more relevant for your type of manuscript. If no published checklist exists please create one as a table 
from the list of requirements in your chosen guideline. If your study design does not have a relevant 
publishing guideline please review closest matches and use the most appropriate with an explanation. 
Yes, STROBE guidelines are 
included.
Word count WHY: Because readers want to find the core information quickly.
Does your paper adhere to our word count for your article type? Please insert number of words in the 
box to the right. Remember that tables, figures, qualitative data extracts and references are not included 
in the word count. 
Word count : 3400  (including 
acknowledgement and funding)
Figures and tables 
and/or quotations
WHY: Because readers want to find the core information quickly. 
Have you adhered to our guidelines on the number of tables and figures for your article type? 
Data (e.g. quotations) for qualitative studies are not included in the word count, and we prefer that they 
are integrated into the text (e.g. not in a separate table). 
Yes, we have included 6 
tables/figures.
Study registration WHY: Because this means readers understand how you planned your study
Where appropriate have you included details (including reference number, date of registration and URL) 
of study registration on a database e.g. trials or review database. If your study has a published protocol, 
is this referenced within the paper? 
We have included information 




WHY: So readers can understand the full context of your study
If there are other publications from this study are these referenced within the body of the paper? Please 
do not reference papers in preparation or submitted, but in-press publications are acceptable. 
One previous publication is 
referenced within the body of the 
paper.
Scales, measures or 
questionnaires
WHY: So readers can understand your paper in the context of this information
If your study primarily reports the development or testing of scales/measures or questionnaires have 
you included a copy of the instrument as a supplementary file? 
Not relevant as this is not 
development of new instrument.
Abbreviations WHY: Because abbreviations make a paper hard to read, and are easily misunderstood
Have you removed all abbreviations from the text except for extremely well known, standard 
abbreviations (e.g. SI units), which should be spelt out in full first? We do not allow abbreviations for 
core concepts such as palliative or end of life care. 
Only the abbreviation QLQ-C30 
for the well-known quality of life 
questionnaire have been spelt 





WHY: We will only publish ethically conducted research, approved by relevant bodies
Have you given full details of ethics/governance/data protection approvals with reference numbers, full 
name of the committee(s) giving approval and the date of approval?  If such approvals are not required 
Approval for Regional Committee 
for Medical and Health Research 
Ethics with reference number is 



































































have you made it explicit within the paper why they were not required. Are details of consent 
procedures clear in the paper?
included and details of consent 
procedures are clear in the paper.
Date(s) of data 
collection
WHY: So readers understand the context within which data were collected
Have you given the dates of data collection for your study within the body of your text? If your data are 
over 5 years old you will need to articulate clearly why they are still relevant and important to current 
practice. 
Months of data collection for our 
study are included in text. 
Structured 
discussion
WHY: So readers can find key information quickly
Papers should have a structured discussion, with sub headings, summarising the main findings, 
addressing strengths and limitations, articulating what this study adds with reference to existing 
international literature, and presenting the implications for practice. 
Our discussion is clearly divided 
into sections discussing the issues 
mentioned. 
Case reports WHY: So that participants are protected, and its importance made clear
If your study is a case report have you followed our clear structure for a case report, including 
highlighting what research is needed to address the issue raised?  Have you made clear what consent 
was required or given for the publication of the case report? Have you provided evidence of such 




WHY: So readers understand the context of the research
Have you included a funding declaration according to the SAGE format?  Are there acknowledgements to 
be made? Have you stated where data from the study are deposited and how they may be available to 
others? Have you conflicts of interest to declare?
Acknowledgements have been 
made, funding and information 
about COI have been included. 
According to Norwegian 
regulations we are not allowed to 
transfer data to make them 
available to others, and this has 
thus not been included in the 
manuscript. We have to ask for 
permission from the regional 
ethical committee about making 
our data available for other 
interested parties, and if 
permission is given data need to 
be accessed locally by visiting our 
institution. 
Supplementary WHY: So the context is clear, but the main paper succinct for the reader No supplementary material 

































































data and materials Is there any content which could be provided as supplementary data which would appear only in the 
online version of accepted papers? This could include large tables, full search strategies for reviews, 
additional data etc. 
provided with this paper
References WHY: So people can easily find work you have referenced
Are your references provided in SAGE Vancouver style? You can download this style within Endnote and 
other referencing software.




Can you assert that you are submitting your original work, that you have the rights in the work, that you 
are submitting the work for first publication in the Journal and that it is not being considered for 
publication elsewhere and has not already been published elsewhere, and that you have obtained and 
can supply all necessary permissions for the reproduction of any copyright works not owned by you.
We are submitting our original 
research that has not been 
submitted elsewhere.
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